Organigram Holdings Inc. (TSE:OGI – Free Report) – Research analysts at Atb Cap Markets decreased their FY2025 earnings per share estimates for shares of Organigram in a report issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings per share of ($0.13) for the year, down from their previous forecast of ($0.12). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share.
OGI has been the subject of a number of other reports. Canaccord Genuity Group decreased their target price on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a research report on Monday, December 9th. ATB Capital reduced their target price on Organigram from C$5.25 to C$3.50 in a report on Tuesday.
Organigram Price Performance
OGI opened at C$2.22 on Thursday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95. The firm has a market cap of C$241.03 million, a P/E ratio of -0.88, a PEG ratio of 0.42 and a beta of 1.13. Organigram has a fifty-two week low of C$1.61 and a fifty-two week high of C$3.95. The firm has a 50-day moving average of C$2.26 and a 200 day moving average of C$2.30.
Insider Activity at Organigram
In other news, Senior Officer Paolo De Luca sold 12,014 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total value of C$30,275.28. 31.32% of the stock is owned by insiders.
Organigram Company Profile
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
See Also
- Five stocks we like better than Organigram
- 3 Fintech Stocks With Good 2021 Prospects
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Most active stocks: Dollar volume vs share volume
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What is a buyback in stocks? A comprehensive guide for investors
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.